fimasartan and Arrhythmias--Cardiac

Fimasartan (BR-A-657) is an angiotensin II receptor antagonist, recently approved as an antihypertensive agent.. This study aimed to investigate whether administration of fimasartan has an effect on the steady-state pharmacokinetics of digoxin.. An open-label, two-period, two-treatment, single-sequence, crossover study was conducted in 14 healthy male volunteers. On the first day of each 7-day treatment period, subjects received a loading dose of digoxin 0.5 mg, either alone or together with fimasartan 240 mg in the morning, followed by an additional dose of digoxin 0.25 mg after 6 h. On the subsequent 6 days, digoxin 0.25 mg, either alone or with fimasartan 240 mg was administered once daily. Serial blood samples for pharmacokinetics were collected up to 24 h after the last administration in each period.. The geometric mean ratio and 90% confidence intervals (CI) for the Cmax,ss and AUCτ,ss of digoxin (with/without fimasartan) were 1.307 (1.123 - 1.520) and 1.087 (1.015 - 1.165), respectively. Study medications were well-tolerated without serious adverse events or clinically meaningful changes.. Coadministration of fimasartan with digoxin does not result in clinically significant changes of digoxin pharmacokinetics at steady-state in healthy subjects.

Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Area Under Curve; Arrhythmias, Cardiac; Biphenyl Compounds; Cardiotonic Agents; Cross-Over Studies; Digoxin; Female; Heart Failure; Humans; Male; Pyrimidines; Tetrazoles; Young Adult